profit from every $100 of sales.
$0$100
Haemonetics
$122.94+0.19% today
+66.3% in 1 year
1-year low $52.241-year high $127.42
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2021 to 2026.
0%20% a year
You pay $57.53 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Haemonetics sold, what it kept, and what it did with the cash.
Sales went from $1.17 billion in 2023 to $1.33 billion in 2026, with $97.3 million of profit last year.
SalesProfit
Haemonetics handed back 67% of the cash it generated last year.
Buybacks $175M
Free cash flow 2026$260M
Bought back its own shares$175M
Paid as dividends–
Cash vs. debt$245M vs. $1.2B
Haemonetics vs. similar companies
Haemonetics grows in the middle of these 5 and is the most expensive for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Haemonetics | 57.5× · Expensive | ||
 Abbott Laboratories | 28.8× · Fair price | ||
 Medtronic | 27.4× · Fair price | ||
 Stryker | 36.3× · Expensive | ||
 Edwards Lifesciences | 57.4× · Expensive |
AI analysis
An AI analyst reads Haemonetics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| 870 | 993 | 1,169 | 1,309 | 1,361 | 1,334 | |
| 398 | 506 | 615 | 692 | 749 | 788 | |
| – | – | 156 | 175 | 201 | 241 | |
| 174 | 178 | 249 | 262 | 337 | 268 | |
| 79 | 43 | 115 | 118 | 168 | 97 | |
| 1.55 | 0.84 | 2.24 | 2.29 | 3.31 | 2.05 | |
| 45.7% | 50.9% | 52.6% | 52.8% | 55.0% | 59.0% | |
| – | – | 13.3% | 13.4% | 14.8% | 18.1% | |
| 9.1% | 4.4% | 9.9% | 9.0% | 12.3% | 7.3% |
Balance sheet
| In millions of USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Total assets | 1,820 | 1,860 | 1,935 | 2,196 | 2,451 | 2,396 |
| Cash | 192 | 259 | 284 | 179 | 307 | 245 |
| Total debt | 708 | 774 | 766 | 808 | 1,225 | 1,225 |
| Total liabilities | – | – | 1,117 | 1,236 | 1,630 | 1,600 |
| 732 | 749 | 818 | 960 | 821 | 796 | |
| 51 | 51 | 51 | 51 | 51 | 47 | |
| 4.9% | 4.2% | 7.8% | 7.4% | 8.6% | 6.1% | |
| 10.9% | 5.8% | 14.1% | 12.2% | 20.4% | 12.2% |
Cash flow
| In millions of USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| 109 | 172 | 273 | 182 | 182 | 293 | |
| 37 | 97 | 191 | 38 | 39 | 33 | |
| 72 | 76 | 82 | 144 | 142 | 260 | |
| Dividends paid | – | – | – | – | – | – |
| 0 | 0 | 75 | 0 | 225 | 175 | |
| 26 | 24 | 26 | 28 | 30 | 34 |
Valuation
- 57.5×
- 23.2×
- 10.00
- 6.9×
- 4.2×
- 21.5×
- 24.5×
- 4.7%
- 1.7%
- 0.0%
Profitability
- 59.0%
- 18.1%
- 7.3%
- 29.8%
- 6.3%
- 7.6%
- 11.3%
- 4.1%
- 11.0%
- 4.5%
Growth
- +8.9%
- +5.8%
- +82.8%
- –
- −2.7%
Financial health
- 3.6×
- 1.54
- 51.1%
- 5.5×
- 2.95
- 1.87
- 0.56
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 45%of 946
Top 28%of 872
Bottom 19%of 563
Bottom 42%of 868
Top 23%of 986
What analysts expect
- Average price target
- $84.60
- Range
- $70.00 – $94.00
- 4 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | 1.29 | 1.28 | +0.8% |
| Feb 5, 2026 | 1.31 | 1.27 | +3.1% |
| Nov 6, 2025 | 1.27 | 1.12 | +13.4% |
| Aug 7, 2025 | 1.10 | 1.01 | +8.9% |
| May 8, 2025 | 1.24 | 1.22 | +1.6% |
| Feb 6, 2025 | 1.19 | 1.18 | +0.8% |
| Nov 7, 2024 | 1.12 | 1.09 | +2.8% |
| Aug 8, 2024 | 1.02 | 1.03 | −1.0% |
News
Haemonetics Corporation Q2 2027 Earnings Call SummaryYahoo Finance · Nov 5, 2026Haemonetics wins approval of PerQseal Elite vascular closure systemSeeking Alpha · Oct 19, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
47No pass
Benjamin Graham
38No pass
Philip Fisher
42No pass
Peter Lynch
21No pass
Joel Greenblatt
3No pass
Charlie Munger
37No pass
Terry Smith
41No pass
Questions about Haemonetics
Is Haemonetics a good stock to buy?
A business with weak numbers, but the price is high. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Haemonetics AI analysis
What does Haemonetics do?
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It is in Medical Devices, based in Boston, MA, United States, with 3,009 employees.
Does Haemonetics pay a dividend?
No. Haemonetics does not pay a dividend at the moment; in 2026 it returned $175 million to shareholders by buying back its own shares.
Is Haemonetics stock halal?
Yes. Haemonetics passes our halal screen: its business is permitted and its debt is 22% of its market value, under the 30% limit. How we check
How has Haemonetics stock done over the past year?
Up 66.3% over the past twelve months, to $122.94. It traded between $52.24 and $127.42 and is 3.5% below its high.
Who are Haemonetics's competitors?
The largest listed companies in the same industry are Abbott Laboratories, Medtronic, Stryker and Edwards Lifesciences. The peers table on this page compares their profit, growth and price with Haemonetics's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.